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Summary Objective: The aims of our study were to evaluate whether deﬁcits in
color vision exist in epileptic adolescents, to study if monotherapy with valproic acid
(VPA) and carbamazepine (CBZ) can affect color vision, and to determine the possible
relationship between abnormal color vision tests and AEDs dosage and their serum
concentrations. Patients: We examined 45 epileptic patients before the beginning of
therapy and after 1 year of VPA or CBZ monotherapy and 40 sex- and age-matched
healthy controls. Methods: Color vision was evaluated with Farnsworth Munsell 100
(FM100) hue test and achromatic and short-wavelength automated perimetry (SWAP).
Statistical analysis: To evaluate intergroup differences we used ANOVA with Scheffe’s
post hoc test, when appropriate. Repeated measures ANOVA was used to evaluate
the intragroup modiﬁcations of total error score (TES) and perimetric threshold dur-
ing the follow-up. Pearson’s correlation test was performed to correlate chromatic
sense and perimetric data and AEDs dosage and serum concentrations. Results: Be-
fore the beginning of therapy, there were no differences in central color vision and
SWAP between controls and epileptic patients. After 1 year, patients treated with
VPA or CBZ showed a deﬁcit in FM100 hue test and SWAP parameters while no sig-
niﬁcant deﬁcit was found in achromatic perimetry. In particular, with the FM100 hue
test a higher number of errors was found in both groups of patients (CBZ patients:
166.00± 27.72 TES; VPA patients: 151.19± 44.09, P < 0.001) in comparison with con-
trols (controls: 109.29± 24.73) and baseline values (CBZ patients: 110.65± 22.9;
VPA patients 107.43± 21.70). With SWAP patients of both groups showed signiﬁcant
variation of foveal threshold (controls: 21.07± 2.01 dB; CBZ patients: 19.35± 1.32,
P < 0.001; VPA patients: 18.88± 1.89, P < 0.001), full-ﬁeld mean threshold perimet-
ric sensitivity (controls: 18.50± 1.24 dB; CBZ patients: 16.60± 1.47, P < 0.001; VPA
patients: 16.23± 1.55, P < 0.001) and mean threshold perimetric sensitivity of the
three evaluated subareas of the visual ﬁeld (area 1 controls: 21.01± 1.15; CBZ pa-
tients: 19.45± 1.74, P = 0.001; VPA patients: 18.25± 1.61, P < 0.001; area 2 con-
trols: 18.40± 1.43; CBZ patients: 16.07± 1.58, P < 0.001; VPA patients: 16.13± 1.46,
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P = 0.001; area 3 controls: 17.20± 1.49; CBZ patients: 14.28± 1.51, P < 0.001; VPA
patients: 14.31± 2.90, P = 0.001). Conclusions: Our study demonstrates that treat-
ment with VPA or CBZ can affect signiﬁcantly both central and paracentral color
vision after a short treatment period.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Previous studies have suggested that antiepilep-
tic drugs (AEDs) may have an inﬂuence on visual
functions.1—7 In particular, carbamazepine (CBZ)
and valproic acid (VPA) can produce a signiﬁcant
impairment of color perception.8,9 Recent studies
on visual function have indicated that epilepsy pa-
tients treated with CBZ or VPA have an accumula-
tion of errors along the blue axis in the Farnsworth
Munsell 100 (FM100) hue test.3 Moreover, the color
contrast tests differentiate visual system disor-
ders even when visual impairment is still mild;
therefore, color contrast evaluation may be more
sensitive than conventional luminance tests.10,11
In spite of several papers that have investigated
visual perception tests in epileptic patients receiv-
ing AEDs, the data in the literature are conﬂicting;
nevertheless there is no study carried out in ado-
lescents with epilepsy and only a few studies have
compared color perception in epileptic patients
receiving different AEDs or monotherapy.1—11
The aims of our study were to evaluate whether
deﬁcit exists in color vision in epileptic children
and adolescents, to study if the treatment with
AEDs monotherapy can affect color vision mea-
sured with three different tests and to determine
the possible relationship between abnormal color
vision tests and AEDs dosage and their serum
concentrations.
Patients
We studied 45 epileptic adolescents (16 males and
29 females, mean age 15.71± 2.01 years: range
11—18), suffering from various types of epilepsy.
Patients were recruited from the Departments of
Pediatrics and Ophthalmology, University of Chieti
in Italy, and they were newly diagnosed and treat-
ment free prior to the study.
Patients with familiar and/or personal history
of congenital color disturbances with the Ishihara
color test, a history of ocular trauma or pathology
or poor vision were excluded.
Patients included in this study were examined be-
fore and after 1 year of therapy with different AEDs
monotherapy. None of the studied patients com-
plained of color vision disturbances.
After the baseline evaluation, the patients were
subdivided into two groups according to their ther-
apy: 29 patients (19 females, 10 males; mean age
13.5± 1.8 years) treated with CBZ and 16 patients
(10 females, 6 males; mean age 16.4± 2.1 years)
treated with VPA. The AED used was chosen ac-
cording to the type of epilepsy of the patients; CBZ
was the drug used particularly in partial epilep-
sies, whereas VPA was primarily used in primary
generalized epilepsies. Gender and sex ratio were
similar in the two groups. In the two groups of
patients, the AEDs were prescribed at the nor-
mal dosage and all serum levels of AEDs were
within the therapeutic range during the time of the
study.
Forty healthy sex- and age-matched children
served as controls which were not treated with any
AEDs and fulﬁlled all inclusion criteria.
Informed consent was obtained by the parents
and assent by the adolescents; consent was ob-
tained also in the control groups. The study was ap-
proved by the Ethical Committee of the University
of Chieti.
Before the beginning of the study, detailed oph-
thalmological evaluation was performed by one
of the authors (L.L.) on each patient and control,
which included: visual acuity, slit-lamp biomi-
croscopy, intraocular pressure measurement, direct
and indirect ophthalmoscopy, fundus retinography.
All these examinations were normal.
All patients and controls underwent the follow-
ing monocular examinations before the beginning
of therapy, testing the right eye ﬁrst: (1) chro-
matic sense (FM100 hue test) with the evaluation
of total error score (TES); (2) two white-on-white
threshold visual ﬁelds, performed at least 2 days
before the test visual ﬁeld, to reduce learning
effect, not evaluated in the study; and (3) cen-
tral static automated perimetry (pupil size greater
than 3mm), performed with both white-on-white
and blue-on-yellow stimuli (short-wavelength au-
tomated perimetry–—SWAP).
The previously described ophthalmological eval-
uation was performed again at the end of the
follow-up.
VPA and CBZ serum concentrations were deter-
mined on the same day of the second ophthalmolog-
ical evaluation, by a capillary gas chromatography
method.
Color vision in epileptic adolescents 413
Methods
The FM100 hue test
This test consists of colored caps as previously
described.12,13 In detail, there are four boxes in
this test; the ﬁrst includes the hues from red to
yellowish green, the second from yellowish green
to bluish green, the third from bluish green to vio-
let, and the fourth from violet to red. The testee
has to arrange the caps according to the hues from
the ﬁrst to the last ﬁxed hue of the box. The order
of presentation of the boxes was varied randomly
between patients. No time limit was prescribed
and the subjects were allowed to correct each of
his arrangements. Each patient performed the test
under standard lighting conditions using natural
daylight in sunny days. In presence of cloudy days
the test was postponed. Each eye was tested sepa-
rately with correction of refractive defects. After
completion of the test TES values were calculated
for each patient using the Farnsworth method. The
main axis of color confusion was determined for
each test.
Achromatic and short-wavelength
automated perimetry
Static perimetry was performed using the full-
threshold 24-2 program of a modiﬁed Humphrey
Field Analyser 640 (Humphrey Instruments, San
Leandro, CA, USA).
The test was performed in both eyes. Foveal
threshold and mean threshold perimetric sensitiv-
ity for each group, for each area and for each test
(achromatic perimetry and SWAP) were evaluated.
A subdivision of the visual ﬁeld in three concentric
areas was performed as previously described.14
Area 1 extends from the center up to 9◦, area 2
from 9 up to 18◦, and area 3 from 18 up to 24/30◦.
Both for achromatic perimetry and SWAP we
used parameters and technique as previously
described.15
For achromatic perimetry, the parameters used
were background luminance, 31.5 apostilb; stimu-
Table 1 Central color vision tested with FM100 hue test in CBZ and VPA epileptic patients and in control subjects.
Cases (n) Baseline (TES) After therapy or no therapy (TES) Percentage change from baseline
CBZ patients 29 110.65± 22.9 166.00± 27.72* +50.02
VPA patients 16 107.43± 21.70 151.19± 44.09* +40.73
Controls 40 109.11± 22.1 109.29± 24.73 +0.16
Data are means± S.D. TES: total error score.
* P < 0.001 vs. baseline and controls.
lus size, Goldmann III; and stimulus color, white.
The background illumination was extinguished us-
ing standard Humphrey software. A bright yellow
background of 80.9 cd/m2, producing a retinal illu-
minance of ∼2.8 photopic trolands was produced
using a carousel projector mounted on the left side
of the perimeter cabinet as suggested by Sample
and Weinreb.16 Wratten #12 ﬁlters were placed in
front of all background sources to produce a yel-
low background. Then, we adjusted and calibrated
the background until it displayed equal luminance
across the central 30◦ of the visual ﬁeld. A ﬁlter
holder was placed in the stimulus light path just be-
hind the perimeter’s shutter box, and a 440-nm in-
terference ﬁlter (half-band-width of 4 nm) was in-
serted into the holder.16 The modiﬁcation for SWAP
became operative after the instrument had per-
formed its standard internal calibration routine.
Statistical analysis
All data are presented as the means± S.D. For
statistical analysis only the right eye was evalu-
ated. The statistical analysis was performed with
the SPSS/PC program (Release 6.0, 444. Chicago,
IL, USA). To evaluate intergroup differences we
used ANOVA with Scheffe’s post hoc test, when ap-
propriate. Repeated measures ANOVA was used to
evaluate the intragroup modiﬁcations of TES and
perimetric threshold during the follow-up.
To determine if there was a signiﬁcant correlation
between chromatic sense and perimetric data and
AEDs dosage and serum concentrations, Pearson’s
correlation test was performed.
P values <0.05 were considered statistically sig-
niﬁcant.
Results
The FM100 hue test
At the beginning of the study, all epileptic adoles-
cents showed TES values similar to control values
(Table 1).
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At the end of the follow-up a signiﬁcant
(P < 0.001) higher number of errors was found in
both groups of patients in comparison with controls
and baseline values (Table 1). In particular, TES val-
ues were above the normal age-dependent ranges
in 14 CBZ patients (48.28%) and in 7 VPA patients
(43.75%). In all these patients the greatest number
of errors was in the third (green-blue) box of the
FM100 hue test. In 11 CBZ patients (37.93%) and
in 6 VPA patients (37.50%) the main axis of color
confusion was in blue-yellow area. In other cases
it was not possible to determine a preferential
confusion axis.
Achromatic perimetry
Mean test time was 13.45min (±3.76) for patients
and 13.17min (±3.47) for controls. In all cases of
both groups, the false positives, negatives, and ﬁx-
ation losses were below 15%. At the beginning of
the study both foveal threshold and full-ﬁeld and
Table 2 Foveal threshold tested with achromatic and color perimetry in CBZ and VPA epileptic patients and in
control subjects.
Cases (n) Baseline (dB) After therapy or
no therapy (dB)
Percentage change
from baseline
Achromatic perimetry
CBZ patients 29 33.55± 1.45 33.01± 1.41 −1.61
VPA patients 16 33.19± 1.11 33.31± 1.54 +0.36
Controls 40 33.16± 1.09 33.24± 1.08 +0.24
Color perimetry
CBZ patients 29 21.66± 1.90 19.35± 1.32* −10.67
VPA patients 16 22.06± 2.75 18.88± 1.89* −14.42
Controls 40 21.03± 2.25 21.07± 2.01 +0.19
Data are means± S.D. dB: decibel.
*P < 0.001 vs. baseline and controls.
Table 3 Full-ﬁeld mean perimetric sensitivity tested with achromatic and color perimetry in CBZ and VPA epileptic
patients and in control subjects.
Cases (n) Baseline (dB) After therapy or
no therapy (dB)
Percentage change
from baseline
Achromatic perimetry
CBZ patients 29 29.82± 0.93 29.72± 0.99 −0.33
VPA patients 16 29.67± 0.81 30.02± 0.97 +1.17
Controls 40 29.50± 0.60 29.74± 0.50 +0.81
Color perimetry
CBZ patients 29 18.90± 1.35 16.60± 1.47* −12.17
VPA patients 16 18.73± 1.35 16.23± 1.55* −13.35
Controls 40 18.60± 1.25 18.50± 1.24 −0.54
Data are means± S.D. dB: decibel.
*P < 0.001 vs. baseline and controls.
subareas mean sensitivities were similar in the two
groups of patients and in controls (Tables 2 and 3).
At the end of the follow-up, patients of both
groups showed no signiﬁcant change of mean test
time, foveal threshold, mean full-ﬁeld threshold
perimetric sensitivity, and mean threshold peri-
metric sensitivity of the three evaluated subareas
(Tables 4—6).
SWAP
Mean test time was 16.32min (±4.12) for patients
and 16.27min (±3.91) for controls. In all cases of
both groups, the false positives, negatives, and ﬁx-
ation losses were below 15%.
Foveal threshold and full-ﬁeld mean threshold
perimetric sensitivity of both groups of patients, at
the beginning and at the end of the follow-up is
shown in Tables 2 and 3.
The subdivision of the visual ﬁelds in three con-
centric areas showed similar results in the three
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Table 4 Mean perimetric sensitivity in area 1 (0—9◦) of the visual ﬁeld tested with achromatic and color perimetry
in CBZ and VPA epileptic patients and in control subjects.
Cases (n) Baseline (dB) After therapy or
no therapy (dB)
Percentage change
from baseline
Achromatic perimetry
CBZ patients 29 31.48± 1.92 31.17± 1.61 −0.98
VPA patients 16 31.13± 1.99 31.56± 1.87 +1.38
Controls 40 31.30± 1.55 31.25± 1.45 −0.15
SWAP
CBZ patients 29 21.10± 1.35 19.45± 1.74* −7.81
VPA patients 16 21.00± 1.27 18.25± 1.61* −13.10
Controls 40 21.00± 1.25 21.01± 1.15 +0.05
Data are means± S.D. dB: decibel.
*P = 0.001 vs. baseline and controls.
Table 5 Mean perimetric sensitivity in area 2 (10—18◦) of the visual ﬁeld tested with achromatic and color
perimetry in CBZ and VPA epileptic patients and in control subjects.
Cases (n) Baseline (dB) After therapy or no
therapy (dB)
Percentage change
from baseline
Achromatic perimetry
CBZ patients 29 29.48± 1.15 28.48± 1.18 −3.39
VPA patients 16 29.25± 0.68 29.50± 0.89 +0.85
Controls 40 29.35± 1.01 29.45± 1.21 +0.34
Color perimetry
CBZ patients 29 18.59± 1.50 16.07± 1.58* −13.56
VPA patients 16 18.00± 1.93 16.13± 1.46* −10.39
Controls 40 18.60± 1.53 18.40± 1.43 −1.08
Data are means± S.D. dB: decibel.
*P < 0.001 vs. baseline and controls.
Table 6 Mean perimetric sensitivity in area 3 (>18◦) of the visual ﬁeld tested with achromatic and color perimetry
in CBZ and VPA epileptic patients and in control subjects.
Cases (n) Baseline (dB) After therapy or
no therapy (dB)
Percentage change
from baseline
Achromatic perimetry
CBZ patients 29 28.79± 1.42 28.48± 1.18 −1.08
VPA patients 16 28.63± 1.15 29.00± 0.97 +1.29
Controls 40 28.50± 1.35 28.45± 1.25 −0.18
Color perimetry
CBZ patients 29 17.07± 1.41 14.28± 1.51* −16.35
VPA patients 16 17.19± 1.38 14.31± 2.90* −16.75
Controls 40 17.10± 1.39 17.20± 1.49 −0.59
Data are means± S.D. dB: decibel.
*P < 0.001 vs. baseline and controls.
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subareas. At the end of follow-up, in both groups of
patients in all evaluated subareas a signiﬁcant de-
crease of threshold perimetric sensitivity was found
(Tables 4—6).
Finally, no signiﬁcant correlation was found be-
tween daily dosage and serum levels of AEDs and
the results of the color vision tests.
Discussion
The present study suggests that epileptic patients
do not have color vision dysfunction but they show
signiﬁcant disturbances after 1 year of treatment
with VPA and CBZ monotherapy.
In recent years, many authors have suggested
that adult epileptic patients treated with these
AEDs can have this side effect.2—7,13 We have stud-
ied the effect of CBZ and VPA on visual perception
using three different methods. In particular, we
have evaluated color vision both in the ﬁxation
point using the FM100 hue test and for the ﬁrst
time, in the paracentral area using perimetry in the
blue-yellow axis. Moreover, achromatic perimetry
was performed in all patients.
The FM100 hue test is the most sensitive test for
detection of color discrimination deﬁcit but it eval-
uates only foveal color vision. This technique has
been widely used in other studies because it is a
commonly available reference for the description
of a color perception deﬁcit.17 Mild subclinical im-
pairment of color perception is often one of the ear-
liest signs of visual dysfunction.1 It is interesting to
underline that we found an impressive consistency
of the TES values for the control group before and
after treatment: this fact suggests an excellent re-
producibility of the technique.
Particularly, in many ocular affections (e.g. mac-
ular disease, diabetes, glaucoma), it has been
demonstrated that color vision impairment is an
early sign of disease. Furthermore, many papers
have underlined the role of SWAP in the early
diagnosis of many other diseases.15,16,18,19 Re-
cent studies carried out SWAP visual ﬁeld testing
on VGB-treated epilepsy patients.20,21 Daneshvar
et al.20 identiﬁed SWAP defects outside 10◦, while
Roff Hilton et al. found defects within the cen-
tral 10◦ ﬁeld. In our study we identiﬁed defects
dispersed both within the central 10◦ ﬁeld and in
outside the of 10◦ ﬁeld.
It is well known that color vision is a sensitive
indicator of altered perception or transmission of
the neurosensorial signal: it relies on a very sub-
tle balance of the outputs of the three different
cone photoreceptors on postreceptoral retinal neu-
rons. Moreover, achromatic perimetry is not useful
in the detection of the vision abnormalities caused
by these AEDs while signiﬁcant abnormalities have
been found in both groups of patients using the
SWAP. For the ﬁrst time we have compared achro-
matic and SWAP for the evaluation of this side ef-
fect of AEDs: from our experience, SWAP seems to
be very useful in determining that color deﬁcit is lo-
cated in foveal area and in parafoveal area (0—9◦)
and also up to 30◦.
According to other studies,4,13,22 our ﬁndings sug-
gest that the effect of CBZ and VPA on calcium and
sodium membrane conductances may play a role
in color vision deﬁcits induced by these AEDs. CBZ
and VPA operate by blocking voltage-dependent
sodium channels, but it has been suggested that
VPA also down-regulates the function of the T-type
calcium channel and/or GABA receptor channel. It
is likely that AEDs have a negative effect on the
retinal cell layer by changes induced upon gluta-
mate and other neurotransmitters. It has not yet
been demonstrated whether this negative effect
is more pronounced on photoreceptors and/or on
on-off receptors of bipolar cells. The selective loss
of short-wavelength-sensitive cone signals (blue),
found in our and other studies,2 can be explained
by anatomical and physiological differences be-
tween the blue-yellow and red-green systems.23
In fact, it is well known that both visual acuity
and contrast sensitivity are poorer in blue light
than in red or green light.24,25 This phenomenon
may be due in part to the relative paucity of
the short-wavelength-sensitive cones compared
to medium and long-wavelength-sensitive cones.
Moreover, blue light is color contrasted with yel-
low light and is encoded in the color opponent
and double opponent cells that signal simulta-
neous contrast of blue and yellow in adjacent
locations. The possibility to evaluate speciﬁ-
cally central visual ﬁeld, avoiding to stimulate
all sensitive cones using white stimuli, allows
an earlier diagnosis of color visual impairment
in several ocular diseases, such as diabetes and
glaucoma.12,14—16
We did not ﬁnd a signiﬁcant correlation between
daily dosage and/or serum levels of AED and the
results of vision tests. This lack of correlation, re-
ported also by other authors2,4,7 can be explained
by the several mechanisms involved in the vision
function that probably is not directly affected only
by AEDs.
Furthermore, computerized perimetry, being a
fully computer-controlled system, avoids errors due
to the human intervention or interpretation; it al-
lows sensitive statistical analysis very useful in the
early diagnosis and long-term follow-up of several
ocular affections.
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It is well known that the trichromatic properties
of human color vision are easily demonstrable out
to between 20 and 30◦ way from ﬁxation: this fact
can explain the usefulness of SWAP.
In conclusion, although the visual deﬁcits are not
severe enough to produce subjective visual com-
plaints, our study conﬁrms that epileptic patients
treated with VPA and CBZ can show color vision de-
fects, in particular for blue vision and that these
defects are well evidenced by the FM100 hue test.
These abnormalities are present not only in the
foveal area but also in the peripheral areas. More-
over, while achromatic perimetry seems to be an in-
sensitive technique to these changes, SWAP is more
sensitive capable detecting early color dysfunction
not only in central but also in peripheral areas.
Consequently, we advise clinicians to carry out this
evaluation in epileptic patients who are treated
with VPA and/or CBZ. At this stage, the study can-
not clarify if the effects on color vision are transient
or chronic and if they are reversible.
References
1. Mecarelli O, Rinalduzzi S, Accornero N. Changes in color
vision after a single dose of vigabatrin or carbamazepine in
healthy volunteers. Clin Neuropharmacol 2001;24:23—6.
2. Bayer AU, Thiel HJ, Zrenner E, Dichgans J, Kuehn M, Paulus
W, et al. Color vision tests for early detection of antiepilep-
tic drug toxicity. Neurology 1997;48:1394—7.
3. Nousiainen I, Kalvainen R, Mantyjarvi M. Color vision in
epilepsy patients treated with vigabatrin or carbamazepine
monotherapy. Ophathalmology 2000;107:884—8.
4. Lopez L, Thomson A, Rabinowicz AL. Assessment of colour
vision in epileptic patients exposed to single-drug therapy.
Eur Neurol 1999;41:201—5.
5. Steinhoff BJ, Freudenthaler N, Paulus W. The inﬂuence
of established and new antiepilectic drugs on visual per-
ception. I. A placebo-controlled, double-blind, single-dose
study in healthy volunteers. Epilepsy Res 1997;29:35—47.
6. Steinhoff BJ, Freudenthaler N, Paulus W. The inﬂuence
of established and new antiepilectic drugs on visual per-
ception. II. A controlled study in patients with epilepsy
under long-term antiepilectic medication. Epilepsy Res
1997;29:49—58.
7. Nousiainen I, Kalvainen R, Mantyjarvi M. Contrast and glare
sensitivity in epilepsy patients treated with vigabatrin or
carbamazepine monotherapy compared with healthy volun-
teers. Br J Ophthalmol 2000;84:622—5.
8. Tomson T, Nilsson BY, Levi R. Impaired visual contrast sen-
sitivity in epileptic patients treated with carbamazepine.
Arch Neurol 1988;45:897—900.
9. Bayer A. Retinale funktionsstorungen bej patienten unter
antikonvulsiver therapje. Medical Thesis, University of Tub-
ingen, 1991.
10. Stamper RL. The effect of glaucoma on central visual func-
tion. Trans Am Ophthalmol Soc 1984;82:792—826.
11. Accornero N, Gregori B, Galiè E, De Feo A, Agnesi R. A new
color VEP procedure discloses asymptomatic visual impair-
ments in optic neuritis and glaucoma suspects. Acta Neurol
Scand 2000;102:258—63.
12. Verrotti A, Lobefalo L, Chiarelli F, Mastropasqua L,
Ciancaglini M, Morgese G. Color vision and persistent mi-
croalbuminuria in children with type-1 (insulin-dependent)
diabetes mellitus: a longitudinal study. Diabetes Res Clin
Pract 1995;30:125—30.
13. Paulus W, Schwarz G, Steinhoff BJ. The effect of
anti-epilectic drugs on visual perception in patients with
epilepsy. Brain 1996;119:539—49.
14. Mastropasqua L, Verrotti A, Lobefalo L, Chiarelli F, Verde-
sea G, Morgese G. Visual ﬁeld defects in diabetic children
without retinopathy: relation between visual function and
microalbuminuria. Acta Ophthalmol Scand 1995;73:125—8.
15. Lobefalo L, Verrotti A, Mastropasqua L, Della Loggia G,
Cherubini V, Morgese G, et al. Blue-on-yellow and achro-
matic perimetry in diabetic children without retinopathy.
Diabetes Care 1998;21:2003—6.
16. Sample PA, Weinreb RN. Color perimetry for assessment of
primary open-angle glaucoma. Invest Ophthalmol Vis Sci
1990;31:1869—75.
17. Pokorny J, Smith VC, Verriest G, Pinckers AJLG. Congenital
and acquired color vision defects. New York: Grune Strat-
ton; 1979.
18. Accornero N, Capozza M, De Feo A, Rinalduzzi S, De Marinis
M, Pecori-Giraldi J, et al. Video color perimetry: impair-
ment in glaucoma suspects. Doc Ophthalmol 2001;103:81—
90.
19. Harwerth RS, Smith III EL, Chandler M. Progressive vi-
sual ﬁeld defects from experimental glaucoma: measure-
ments with white and colored stimuli. Optom Vis Sci
1999;76(8):558—70.
20. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman
A, Zackon D. Symptomatic and asymptomatic visual loss in
patients taking vigabatrin. Ophthalmology 1999;106:1792—
8.
21. Hilton EJ, Cubbidge RP, Hosking SL, Betts T, Comaish IF.
Patients treated with vigabatrin exhibit central visual func-
tion loss. Epilepsia 2002;43:1351—9.
22. MacDonald RL, Kelly KM. Mechanisms of action of currently
prescribed and newly developed antiepilectic drugs [re-
view]. Epilepsia 1994;35(Suppl 4):S41—50.
23. Ahnelt PK, Kolb H. Short-wavelength-sensitive cones: mor-
phology and color-speciﬁc connections. In: Drum B, edi-
tor. Colour vision deﬁciencies XII. Dordrecht: Kluwer; 1995.
p. 285–97.
24. Brindley GS. The summation areas of human colour recep-
tive mechanisms at increment threshold. J Physiol (Lond)
1954;124:400.
25. Green DG. The contrast sensitivity of the colour mechanisms
of the human eye. J Physiol (Lond) 1968;196:415.
